Zhejiang Yangshengtang Biotechnology Co., Ltd.

Primary objectives: To evaluate the safety and tolerability of rHSV-1-APD1 in the treatment of patients with advanced hepatocellular carcinoma, determine the maximum tolerated dose (MTD)/recommended phase II clinical dose (RP2D) and dose-limiting toxicity (DLT). Secondary objectives: To evaluate the biodistribution characteristics of rHSV-1-APD1 in the treatment of patients with advanced hepatocellular carcinoma. To evaluate the preliminary anti-tumor efficacy of rHSV-1-APD1 in the treatment of patients with advanced hepatocellular carcinoma. To explore the pharmacodynamics and immunogenicity of rHSV-1-APD1 in the treatment of patients with advanced hepatocellular carcinoma.

Primary objectives: To evaluate the safety and tolerability of intravenous administration of rHSV-1-APD1 in the treatment of patients with primary central nervous system tumors/brain metastases from solid tumors, and to determine the maximum tolerated dose (MTD)/recommended phase II clinical dose (RP2D) and dose-limiting toxicity (DLT). Secondary objectives: To evaluate the biodistribution characteristics of intravenous administration of rHSV-1-APD1. To evaluate the preliminary anti-tumor efficacy of intravenous administration of rHSV-1-APD1 in patients with primary central nervous system tumors/brain metastases from solid tumors. To evaluate the relationship between the anti-tumor efficacy of intravenous administration of rHSV-1-APD1 in the treatment of patients with primary central nervous system tumors/brain metastases from solid tumors and pharmacodynamic indicators and immunogenicity indicators. To evaluate the relationship between the safety of intravenous administration of rHSV-1-APD1 and immunogenicity indicators.

Primary objective: To evaluate the safety and tolerability of intravenous administration of rHSV-1-APD1 in patients with advanced solid tumors, and to determine the maximum tolerated dose (MTD)/recommended phase II clinical dose (RP2D) and dose-limiting toxicity (DLT). Secondary objective: To evaluate the biodistribution characteristics of intravenous administration of rHSV-1-APD1. To evaluate the preliminary anti-tumor efficacy of intravenous administration of rHSV-1-APD1 in patients with advanced solid tumors. To evaluate the relationship between the anti-tumor efficacy of intravenous administration of rHSV-1-APD1 in patients with advanced solid tumors and pharmacodynamic and immunogenicity indicators. To evaluate the relationship between the safety and immunogenicity indicators of intravenous administration of rHSV-1-APD1 in patients with advanced solid tumors.